Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Yesterday this discussion board started, and it happens to be the day that a report comes out about a blood screening test in Taiwan that has better results. The two points of differentiation are the sample method (blood vs. stool) and the results for precancerous lesions where the sensitivity in the Taiwanese test is more accurate. It may just be over-reaction to the news, but what sort of barriers exist for a test from outside the USA to become a viable alternative? Or is this a sign that Exact Sciences needs to bring additional products to market sooner to justify its valuation? I still think the share of the colon cancer screening market that Exact currently occupies has a lot of room to grow for the foreseeable future. Not in a panic, but not adding shares at this time.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.